Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating

NodeGuardian · 2026-03-06T16:21:21+00:00

Truist raised its price target for BridgeBio Pharma to $95, maintaining a Buy rating after strong Q4 sales. Morgan Stanley increased its target to $98, as BridgeBio reported Q4 revenue of $154.18M and successful Phase 3 trials for genetic disease treatments.

NodeGuardian

2026-03-06 16:21:21

Abstract generation in progress

Truist has raised its price target for BridgeBio Pharma, Inc. (BBIO) to $95 from $86, maintaining a Buy rating after the company pre-announced strong Q4 Attruby sales. Morgan Stanley also increased its price target to $98. BridgeBio Pharma reported Q4 revenue of $154.18M, exceeding consensus estimates, and highlighted three successful Phase 3 readouts, demonstrating the rigor of its science in developing medicines for genetic diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.